Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck dB Segment Context — Pharmaceutical Segment Revenue ($M) ($M)
Postgres DB segment_values (via lib/db.py)
Latest, Q2 2026
14,760
Period ended Jun 30, 2026
Change on a year earlier
+5.1%
14,050 in Q2 2025
History
52 quarters
Since Q1 2013
Sources
45
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | DB Segment Context — Pharmaceutical Segment Revenue ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 14,760 | +5.1% | Form 10-Q (filed 2026-08-07) ↗ |
| Q1 2026 | Mar 31, 2026 | 14,349 | +5.2% | Form 10-Q (filed 2026-05-04) ↗ |
| Q4 2025 | Dec 31, 2025 | 14,843 | +5.7% | Form 10-K (filed 2026-02-24) ↗ |
| Q3 2025 | Sep 30, 2025 | 15,611 | +4.5% | Form 10-Q (filed 2025-11-05) ↗ |
| Q2 2025 | Jun 30, 2025 | 14,050 | -2.5% | Form 10-Q (filed 2025-08-05) ↗ |
| Q1 2025 | Mar 31, 2025 | 13,638 | -2.6% | Form 10-Q (filed 2025-05-02) ↗ |
| Q4 2024 | Dec 31, 2024 | 14,042 | +6.9% | Form 10-K (filed 2025-02-25) ↗ |
| Q3 2024 | Sep 30, 2024 | 14,943 | +4.8% | Form 10-Q (filed 2024-11-06) ↗ |
| Q2 2024 | Jun 30, 2024 | 14,408 | +7.1% | Form 10-Q (filed 2024-08-05) ↗ |
| Q1 2024 | Mar 31, 2024 | 14,006 | +10.1% | Form 10-Q (filed 2024-05-03) ↗ |
| Q4 2023 | Dec 31, 2023 | 13,141 | +7.9% | Form 10-K (filed 2024-02-26) ↗ |
| Q3 2023 | Sep 30, 2023 | 14,263 | +10.0% | Form 10-Q (filed 2023-11-03) ↗ |
| Q2 2023 | Jun 30, 2023 | 13,457 | +5.5% | Form 10-Q (filed 2023-08-07) ↗ |
| Q1 2023 | Mar 31, 2023 | 12,721 | -9.8% | Form 10-Q (filed 2023-05-05) ↗ |
| Q4 2022 | Dec 31, 2022 | 12,179 | +1.2% | Form 10-K (filed 2023-02-24) ↗ |
| Q3 2022 | Sep 30, 2022 | 12,963 | +12.8% | Form 10-Q (filed 2022-11-03) ↗ |
| Q2 2022 | Jun 30, 2022 | 12,756 | +27.8% | Form 10-Q (filed 2022-08-05) ↗ |
| Q1 2022 | Mar 31, 2022 | 14,107 | +52.7% | Form 10-Q (filed 2022-05-05) ↗ |
| Q4 2021 | Dec 31, 2021 | 12,040 | +22.7% | Form 10-K (filed 2022-02-25) ↗ |
| Q3 2021 | Sep 30, 2021 | 11,496 | +18.3% | Form 10-Q (filed 2021-11-05) ↗ |
| Q2 2021 | Jun 30, 2021 | 9,980 | +22.0% | Form 10-Q (filed 2021-08-09) ↗ |
| Q1 2021 | Mar 31, 2021 | 9,238 | -13.3% | Form 10-Q (filed 2022-05-05) ↗ |
| Q4 2020 | Dec 31, 2020 | 9,813 | +240.5% | Form 10-K (filed 2022-02-25) ↗ |
| Q3 2020 | Sep 30, 2020 | 9,714 | -12.4% | Form 10-Q (filed 2021-11-05) ↗ |
| Q2 2020 | Jun 30, 2020 | 8,178 | -21.8% | Form 10-Q (filed 2021-08-09) ↗ |
| Q1 2020 | Mar 31, 2020 | 10,655 | +10.3% | Form 10-Q (filed 2020-05-06) ↗ |
| Q4 2019 | Dec 31, 2019 | 2,882 | -70.7% | Form 10-K (filed 2022-02-25) ↗ |
| Q3 2019 | Sep 30, 2019 | 11,095 | +14.9% | Form 10-Q (filed 2019-11-05) ↗ |
| Q2 2019 | Jun 30, 2019 | 10,460 | +12.7% | Form 10-Q (filed 2019-08-06) ↗ |
| Q1 2019 | Mar 31, 2019 | 9,663 | +8.3% | Form 10-Q (filed 2019-05-08) ↗ |
| Q4 2018 | Dec 31, 2018 | 9,830 | +5.8% | Form 10-K (filed 2019-02-27) ↗ |
| Q3 2018 | Sep 30, 2018 | 9,658 | +5.5% | Form 10-Q (filed 2018-11-06) ↗ |
| Q2 2018 | Jun 30, 2018 | 9,282 | +6.0% | Form 10-Q (filed 2018-08-07) ↗ |
| Q1 2018 | Mar 31, 2018 | 8,919 | +9.0% | Form 10-Q (filed 2018-05-08) ↗ |
| Q4 2017 | Dec 31, 2017 | 9,289 | +4.3% | Form 10-K (filed 2018-02-27) ↗ |
| Q3 2017 | Sep 30, 2017 | 9,156 | -3.0% | SEC Filing ↗ |
| Q2 2017 | Jun 30, 2017 | 8,759 | +0.7% | SEC Filing ↗ |
| Q1 2017 | Mar 31, 2017 | 8,185 | +1.0% | SEC Filing ↗ |
| Q4 2016 | Dec 31, 2016 | 8,904 | -1.4% | SEC Filing ↗ |
| Q3 2016 | Sep 30, 2016 | 9,443 | +5.8% | SEC Filing ↗ |
| Q2 2016 | Jun 30, 2016 | 8,700 | +1.6% | SEC Filing ↗ |
| Q1 2016 | Mar 31, 2016 | 8,104 | -2.0% | SEC Filing ↗ |
| Q4 2015 | Dec 31, 2015 | 9,027 | -3.7% | Form 10-K (filed 2016-02-26) ↗ |
| Q3 2015 | Sep 30, 2015 | 8,925 | -2.3% | Form 10-Q (filed 2015-11-05) ↗ |
| Q2 2015 | Jun 30, 2015 | 8,564 | -5.8% | Form 10-Q (filed 2015-08-06) ↗ |
| Q1 2015 | Mar 31, 2015 | 8,266 | -2.2% | Form 10-Q (filed 2015-05-07) ↗ |
| Q4 2014 | Dec 31, 2014 | 9,370 | – | Form 10-K (filed 2015-02-27) ↗ |
| Q3 2014 | Sep 30, 2014 | 9,134 | -3.6% | Form 10-Q (filed 2014-11-10) ↗ |
| Q2 2014 | Jun 30, 2014 | 9,087 | – | Form 10-Q (filed 2014-08-07) ↗ |
| Q1 2014 | Mar 31, 2014 | 8,451 | -4.9% | Form 10-Q (filed 2014-05-08) ↗ |
| Q2 2013 | Sep 30, 2013 | 9,475 | – | Form 10-Q (filed 2014-11-10) ↗ |
| Q1 2013 | Mar 31, 2013 | 8,891 | – | Form 10-Q (filed 2014-05-08) ↗ |
Breakdown
What makes up db segment context — pharmaceutical segment revenue ($m)
- Pharmaceutical Segment — Cost of Sales ($M)1,731 · Q2 2026
- Pharmaceutical Segment — SG&A Expense ($M)1,437 · Q2 2026
- Pharmaceutical Segment — Segment Profit / Pretax Income ($M)11,612 · Q2 2026
- Animal Health Segment — Revenue ($M)1,775 · Q2 2026
- Animal Health Segment — Cost of Sales ($M)715 · Q2 2026
- Animal Health Segment — SG&A Expense ($M)304 · Q2 2026
- Animal Health Segment — Segment Profit / Pretax Income ($M)636 · Q2 2026
Cite this data
StockData. (2026). Merck DB Segment Context — Pharmaceutical Segment Revenue ($M) ($M), quarterly Q1 2013–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/db_seg_pharma_rev
See every metric in the Merck KPI table. Data updated Oct 26, 2026.